Connect with us

Hi, what are you looking for?

Economy

What do the UK allergic reaction cases mean for Pfizer’s COVID-19 vaccine

Image via Reuters

Britain’s medicines regulator has advised people with a history of significant allergies not to get the Pfizer-BioNTech COVID-19 vaccine after two people reported adverse reactions on the first day of its rollout in the UK.

Here are some questions and answers about the cases and what they might mean.

WHAT EXACTLY HAPPENED?
UK officials said there have been two reports of anaphylaxis and one report of a possible allergic reaction since rollout began. Anaphylaxis can cause throat swelling, breathing trouble, and difficulty swallowing, according to the American Academy of Allergy, Asthma & Immunology. Anaphylaxis is an overreaction of the body’s immune system, which the UK National Health Service describes as severe and sometimes life-threatening.

WHO SHOULD NOT GET THE VACCINE, ACCORDING TO UK REGULATORS?
British regulators initially responded by saying anyone with a history of a significant allergic reaction to a vaccine, medicine or food should not take the shot. An adviser to the group later said it was “tweaking” advice in part to say a food allergy was not a risk.

Late on Wednesday, the UK regulator said anyone with a history of anaphylaxis to a vaccine, medicine or food should not get the vaccine.

Pfizer had excluded people with a history of significant adverse reaction to vaccines or its vaccine’s ingredients from late-stage trials.

HOW DOES THIS AFFECT PROSPECTS FOR U.S. AUTHORIZATION?
US regulators are expected to consider emergency authorization of the Pfizer vaccine soon after a Thursday meeting of advisers.

Moncef Slaoui, who is spearheading the US government’s vaccine development efforts, said on Wednesday he expected the British allergic reactions would be considered in the US authorization process and that people with known severe allergic reactions probably should not take the vaccine until more was understood.

WHAT DO DOCTORS SAY?
Some praised UK regulators’ caution, while others said broad restrictions were not warranted by available evidence.

“For the general population, this does not mean that they would need to be anxious about receiving the vaccination,” said Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine.

What would be wise, he said, would be “for anyone who has known severe allergic reaction such that they need to carry an EpiPen to delay having a vaccination until the reason for the allergic reaction has been clarified.”

Mayo Clinic virologist Gregory Poland, who has advised US regulators, described Britain’s early reaction as “overdoing it,” pointing to the initial response about food allergies, which he said “have nothing to do with this.”

“I would have said, ‘If you’ve had anaphylactic-level reactions to vaccines, we want to know about that so we take extra care,’” he said. “That doesn’t mean I wouldn’t immunize you. But I would do it in a more controlled setting.”

Peter Openshaw, a professor of experimental medicine at Imperial College London, praised the way the reactions had been handled. “The fact that we know so soon about these two allergic reactions and that the regulator has acted on this to issue precautionary advice shows that the monitoring system is working well,” he said.

Mitchell Grayson, director of the division of allergy and immunology at Nationwide Children’s Hospital in Ohio, voiced concern over how the issue might reduce interest in vaccinations. “I’m worried the whole event will cause millions of people to choose not to get vaccinated because of what they heard,” he said.

HOW COMMON ARE SEVERE OR SIGNIFICANT ALLERGIES?
“In the UK in 2012 there were around seven hospital admissions per 100,000 people for severe allergies. This included different triggers such as foods, drugs and insect stings,” said Louisa James, an expert in immunology at Queen Mary University of London. Fatalities remain very rare and have not increased even as hospital admissions have risen in many countries. — Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

By Jenina P. Ibañez, Senior Reporter PHILIPPINE MANUFACTURING activity rose to an eight-month high in November, as new orders increased for the first time...

Economy

THE NATIONAL Government’s outstanding debt swelled to P11.97 trillion as of the end of October as it offered more domestic securities, preliminary data from...

Economy

MOTORISTS experience heavy traffic along Commonwealth in Quezon City on Wednesday. — PHILIPPINE STAR/ MICHAEL VARCAS BANGKO SENTRAL ng Pilipinas (BSP) Governor Benjamin E....

Economy

THE SENATE on Wednesday approved on third and final reading the proposed P5.024-trillion national budget for 2022. Senators unanimously passed the 2022 General Appropriations...

Economy

EVERYTHING’s coming full circle from the boy from Cebu who wanted to write but ended up cooking. Myke “Tatung” Sarthou, celebrity chef, started out...

Economy

1 of 6 THE VIRTUS awards by the Hotel Sales and Marketing Association (HSMA) Philippines continues to honor professionals and institutions in hospitality: a...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.